US pharma major Bristol Myers Squibb is planning a massive $40 billion investment in the country over the next five years.

Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2025.

Sino American biotech BeiGene (Nasdaq: ONC; HKEX: 06160), a global oncology company that will change its name to BeOne ...

US President Donald Trump has signed an executive order attempting to restore a robust domestic manufacturing base for ...

French drugmaker Ipsen (Euronext: IPN) today announced new data from two late-breaking presentations on Iqirvo (elafibranor) ...

UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...

Shares in Danish drugmaker Novo Nordisk were 3% higher on Wednesday afternoon after the company presented its first-quarter ...

NewLimit was founded to develop medicines that add healthy years to each human life. Initially, we thought it would take many ...

California-based Atara Biotherapeutics (Nasdaq: ATRA) revealed that the US Food and Drug Administration (FDA) has lifted the ...

The Russian government will consider registering next-in-class drugs based on data from the second phase of clinical trials ...

Lossmaking Danish pharma ingredients maker Xellia Pharmaceuticals said it could only survive against Chinese competition by ...

US biotech Aldeyra Therapeutics is making another attempt to gain marketing approval for its eye drop treatment reproxalap, a ...